Vertex Pharmaceuticals Incorpor (VRTX) is currently trading at $472.57. Based on 23 Wall Street analysts, the average target price is $554.91, implying a 17.4% upside. The consensus recommendation is BUY.

VRTX

Vertex Pharmaceuticals Incorpor

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$472.57

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$350.00$616.00
Current $472.57
Median: $565.00Mean: $528.40Current: $472.57

Recent price target updates (latest 80)

  • UBSJul 13, 2026

    PT action: Raises

    $545.00 → $585.00

  • Truist SecuritiesJul 13, 2026

    PT action: Raises

    $542.00 → $560.00

  • RBC CapitalJul 7, 2026

    PT action: Raises

    $543.00 → $570.00

  • BairdJul 7, 2026

    PT action: Raises

    $330.00 → $350.00

  • BarclaysMay 6, 2026

    PT action: Raises

    $607.00 → $615.00

  • Canaccord GenuityMay 5, 2026

    PT action: Lowers

    $437.00 → $436.00

  • Morgan StanleyMay 5, 2026

    PT action: Raises

    $612.00 → $616.00

  • BernsteinMay 5, 2026

    PT action: Lowers

    $577.00 → $572.00

  • RBC CapitalMay 5, 2026

    PT action: Raises

    $541.00 → $543.00

  • Canaccord GenuityApr 30, 2026

    PT action: Lowers

    $441.00 → $437.00

  • Morgan StanleyApr 10, 2026

    PT action: Raises

    $596.00 → $612.00

  • Maxim GroupMar 18, 2026

    PT action: Announces

    $0.00 → $575.00

  • Truist SecuritiesMar 11, 2026

    PT action: Raises

    $490.00 → $525.00

  • Morgan StanleyMar 10, 2026

    PT action: Raises

    $570.00 → $596.00

  • B of A SecuritiesMar 10, 2026

    PT action: Raises

    $571.00 → $598.00

  • CitigroupMar 10, 2026

    PT action: Raises

    $575.00 → $585.00

  • OppenheimerMar 10, 2026

    PT action: Raises

    $540.00 → $600.00

  • JefferiesMar 10, 2026

    PT action: Announces

    $0.00 → $580.00

  • HC Wainwright & Co.Mar 10, 2026

    PT action: Raises

    $591.00 → $641.00

  • Canaccord GenuityFeb 17, 2026

    PT action: Raises

    $411.00 → $441.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$554.91

Based on 23 analysts

Analyst Recommendations

Buy (22)Hold (4)Sell (2)

Upside

+17.42%

Market Cap

$119.94B

Financial & Investment Metrics

Next Earnings Date
Aug 3, 2026D-12
P/E Ratio (TTM)28.01
Forward P/E22.17
P/B Ratio6.20
Dividend YieldN/A
Return on Equity (ROE)24.20%
Operating Margin38.13%
Debt to Equity10.26
Beta (Volatility)0.29
52 Week Range$362.50 - $533.67
LowCurrent: $472.57High

Latest News

Daily editorial mentioning VRTX

Price target moves

Healthcare and Tech Dominate as 24 Target Revisions Hit the Wire

The latest sentiment shift across the S&P 500 has been active, with 24 distinct ticker price targets adjusted over the last 14 days, according to data as of July 13, 2026. The activity is concentrated in the Healthcare and IT sectors, where institutional analysts are re-evaluating long-term valuation models despite recent price volatility.

Target changes

The moves reflect a mix of cautious recalibration and optimistic outlooks. UBS was particularly busy, issuing a series of upward revisions for healthcare heavyweights. Notably, the firm boosted LLY from 1250 to 1425 and VRTX from 545 to 585. Meanwhile, TD Cowen took a more selective approach, raising ADI to 460 from 450 while simultaneously lowering its outlook on ISRG twice in the same window—first to 600 and then to 520, signaling significant disagreement within the firm's own modeling trajectory.

Ticker Firm Dir Prior → Current
TSLA Jefferies Up 375 → 400
ISRG TD Cowen Down 585 → 520
FTNT TD Cowen Up 160 → 215
NFLX Oppenheimer Down 120 → 100

Industrial names also saw downward pressure, as TD Cowen trimmed its targets for both LMT and NOC, moving them to 560 and 580, respectively. In the communication services space, the outlook remains fragmented; while UBS lowered GOOGL to 400, the broader market volatility has left some price action feeling disconnected from recent fundamental adjustments.

How this differs from consensus

When we look at the spread between these new targets and the current consensus mean, it is clear that some analysts are leaning into extreme outcomes. For instance, the recent downgrade of NFLX to 100 by Oppenheimer sits at a striking variance compared to the broader market's expectations. This move suggests a fundamental questioning of subscriber growth narratives that the consensus has yet to fully internalize. Conversely, the aggressive upward revision for FTNT to 215 by TD Cowen highlights a divergence in how analysts account for cyber-security demand, placing the firm far ahead of the average valuation model. These target adjustments serve as a reminder that institutional consensus is often a lagging indicator, prone to rapid shifts when firm-level analysts pivot their core growth assumptions.

Read article

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
7/2/2026MCKECHNIE DUNCAN J.OfficerSale at price 519.00 per share.1,541
7/2/2026TATSIS OURANIAOfficerSale at price 524.99 per share.1,500
7/1/2026LIU JOYOfficerSale at price 502.71 per share.828
6/26/2026BOZIC CARMENOfficerSale at price 482.50 per share.596
6/18/2026BOZIC CARMENOfficerSale at price 462.17 per share.1,020
6/15/2026BOZIC CARMENOfficerSale at price 450.00 per share.4,062
6/5/2026BOZIC CARMENOfficerSale at price 450.00 per share.1,745
6/1/2026LIU JOYOfficerSale at price 439.91 per share.828
5/29/2026BOZIC CARMENOfficerSale at price 450.00 per share.1,974
5/15/2026BUNNAGE MARK E.OfficerSale at price 453.45 per share.33

Frequently Asked Questions

Q. What is the current target price and upside for VRTX?

A. The current target price for Vertex Pharmaceuticals Incorpor is $554.91, which implies a 17.4% upside from the current price of $472.57. This is based on the consensus of 23 Wall Street analysts.

Q. What is the current analyst recommendation for VRTX?

A. Currently, there are 4 Strong Buy, 18 Buy, 4 Hold, 1 Sell, and 1 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying VRTX stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer